Mahal Brandon A, Hoffman Karen E, Efstathiou Jason A, Nguyen Paul L
Harvard Medical School, Boston, MA.
Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
Clin Genitourin Cancer. 2015 Jun;13(3):e167-72. doi: 10.1016/j.clgc.2014.12.005. Epub 2014 Dec 9.
Three randomized trials demonstrated that postprostatectomy adjuvant radiotherapy improves biochemical disease-free survival for patients with adverse pathologic features, and 1 trial found adjuvant radiotherapy improves overall survival. We sought to determine whether postprostatectomy radiotherapy (PPRT) utilization changed after publication of the survival benefit in March 2009.
The Surveillance, Epidemiology, and End Results database was used to identify men diagnosed with prostate cancer from 2004 to 2011 who met criteria for enrollment in the randomized trials (positive margins and/or pT3-4 disease at radical prostatectomy). Joinpoint regression identified inflection points in PPRT utilization. Logistic regression was used to evaluate factors associated with PPRT recommendation.
Of 35,361 men, 5104 (14.4%) received a recommendation for PPRT. In joinpoint regression, 2009 was the inflection point in PPRT utilization. In multivariable analysis, PPRT recommendations were more likely after March 2009 than before 15.8% vs. 13.5%, adjusted odds ratio (AOR; 1.09; 95% confidence interval [CI], 1.02-1.16; P = .008), in men with pT3 (vs. pT2, AOR, 2.81; 95% CI, 2.53-3.11; P < .001), pT4 (vs. pT2 AOR, 4.62; 95% CI, 3.85-5.54; P < .001), or margin positive (AOR, 1.46; 95% CI, 1.34-1.58; P < .001) disease and in men who were younger (per year decrease, AOR, 1.02; 95% CI, 1.02-1.03; P < .001), married (AOR, 1.10; 95% CI, 1.02-1.19; P = .01), or lived in metropolitan areas (AOR, 1.30; 95% CI, 1.16-1.47; P < .001).
PPRT recommendations increased after the reporting of a survival benefit in March 2009, but absolute utilization rates remain low, suggesting that the oncologic community remains unconvinced that PPRT is needed for most patients with adverse features. Further work is needed to identify patients who might benefit most from PPRT.
三项随机试验表明,前列腺切除术后辅助放疗可改善具有不良病理特征患者的无生化复发生存率,且一项试验发现辅助放疗可改善总生存率。我们试图确定在2009年3月公布生存获益后,前列腺切除术后放疗(PPRT)的使用情况是否发生了变化。
利用监测、流行病学和最终结果数据库,识别出2004年至2011年被诊断为前列腺癌且符合随机试验入组标准(根治性前列腺切除术后切缘阳性和/或pT3-4期疾病)的男性。连接点回归确定了PPRT使用情况的拐点。采用逻辑回归评估与PPRT推荐相关的因素。
在35361名男性中,5104名(14.4%)接受了PPRT推荐。在连接点回归中,2009年是PPRT使用情况的拐点。在多变量分析中,2009年3月之后接受PPRT推荐的可能性高于之前(15.8%对13.5%,调整后的优势比[AOR]为1.09;95%置信区间[CI]为1.02-1.16;P = 0.008),在pT3期(与pT2期相比,AOR为2.81;95%CI为2.53-3.11;P < 0.001)、pT4期(与pT2期相比AOR为4.62;95%CI为3.85-5.54;P < 0.001)或切缘阳性(AOR为1.46;95%CI为1.34-1.58;P < 0.001)疾病的男性中,以及在年龄较小(每年降低,AOR为1.02;95%CI为1.02-1.03;P < 0.001)、已婚(AOR为1.10;95%CI为1.02-1.19;P = 0.01)或居住在大都市地区(AOR为1.30;95%CI为1.16-1.47;P < 0.001)的男性中。
2009年3月报告生存获益后,PPRT推荐有所增加,但绝对使用率仍然较低,这表明肿瘤学界仍不确信大多数具有不良特征的患者需要PPRT。需要进一步开展工作,以确定可能从PPRT中获益最大的患者。